CoreCap Advisors’s Galectin Therapeutics GALT Stock Holding History

CoreCap Advisors’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.1K	Sell	3,890 -704	-15%	-$1.82K	﹤0.01%	1839
2026 Q1	$12.8K	Hold	4,594	–	–	﹤0.01%	1858
2025 Q4	$19.1K	Hold	4,594	–	–	﹤0.01%	1697
2025 Q3	$19.5K	Hold	4,594	–	–	﹤0.01%	1684
2025 Q2	$9.69K	Hold	4,594	–	–	﹤0.01%	1882
2025 Q1	$5.61K	Sell	4,594 -3,805	-45%	-$5.34K	﹤0.01%	2056
2024 Q4	$10.8K	Buy	8,399 +704	+9%	+$1.69K	﹤0.01%	1742
2024 Q3	$21.2K	Buy	+7,695	New	+$18.9K	﹤0.01%	1532
2024 Q2	–	Sell	-7,695	Closed	-$18.4K	–	1962
2024 Q1	$18.4K	Buy	+7,695	New	+$14.6K	﹤0.01%	1514
2022 Q4	$10.4K	Buy	+9,195	New	+$12.2K	﹤0.01%	1528
2022 Q3	–	Sell	-9,195	Closed	-$12K	–	1108
2022 Q2	$12K	Buy	+9,195	New	+$13.2K	﹤0.01%	1420
2022 Q1	–	Sell	-9,195	Closed	-$19K	–	1115
2021 Q4	$19K	Buy	+9,195	New	+$26.3K	﹤0.01%	1345

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CoreCap Advisors's GALT Position: Q2 2026 in Review

CoreCap Advisors reduced its Galectin Therapeutics (GALT) stake by 15% in Q2 2026, selling an estimated $1.82K and leaving 3,890 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1839.

CoreCap Advisors first reported a position in GALT in Q4 2021 and has held it in 12 quarters since. The position peaked at $21.2K in Q3 2024. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

CoreCap Advisors held 3,890 shares of Galectin Therapeutics worth $18.1K as of Q2 2026.
CoreCap Advisors sold 704 Galectin Therapeutics shares in Q2 2026, an estimated $1.82K.
Galectin Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #1839 holding.
CoreCap Advisors first reported a position in Galectin Therapeutics in Q4 2021 and has held it in 12 quarters since.
CoreCap Advisors's Galectin Therapeutics position peaked at $21.2K in Q3 2024.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.